Background
Tumor-associated macrophages are pivotal drivers of hepatocellular carcinoma (HCC) progression. However, the functional contributions of proliferating macrophages (Prolif Ms) within the tumor microenvironment (TME) remain poorly defined.
M…
Background
Advanced gastric cancer (aGC) exhibits substantial heterogeneity in response to combination immunotherapy. Circulating cell-free DNA (cfDNA) enables non-invasive profiling of tumor dynamics and may provide biomarkers for response prediction…
Neoadjuvant immunotherapy has increased rates of pathological complete response (pCR) in thoracic malignancies and has renewed interest in organ-preserving strategies. In esophageal squamous cell carcinoma (ESCC), the Surgery As Needed for Oesophageal…
Following administration of chimeric antigen receptor (CAR) T-cell therapy, extensive long-term follow-up (LTFU) requirements and complex data collection processes have posed significant challenges for patients and providers. To reassess whether a 15-…
Background
Antigen-specific CD8+ T cells can be in a stem-like programmed cell death protein-1 (PD-1)+TCF-1+ differentiation state that progresses into terminal exhaustion in cancer and chronic infection. These stem-like cells are important, since the…
The gut microbiota has emerged as a critical determinant of therapeutic immunity, shaping responses to immune checkpoint inhibitors, adoptive cellular therapies, and radiotherapy (RT). Interest has grown in whether interventions targeting the microbio…
Background
Myeloid-derived suppressor cells (MDSCs) play a pivotal role in shaping the immunosuppressive tumor microenvironment, thereby driving tumor progression and contributing to resistance to therapy. The surface molecules expressed on MDSCs serv…
Background
Immune checkpoint inhibitors achieve high response rates in relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL), but few treatment options are available for patients who experience failure after PD-1/PD-L1 blockade. T cell immunog…
Autologous tumor-infiltrating lymphocyte (TIL) therapy has recently been approved by the US Food and Drug Administration and Health Canada for the management of patients with advanced melanoma refractory to first-line immune checkpoint inhibitors, wit…
